Posts tagged immunotherapies
Maxim cuts Stellar price target to $4

Maxim Group reduced its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $4 from $7, saying demand for the company’s keyhole limpet hemocyanin (KLH) is a slow climb. The stock was quoted at $2.59 at midday Dec 2.

Read More
Ladenburg starts Bellicum Pharma at buy

Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals (NASDAQ:BLCM) with a “buy” rating and $31 price target. The stock closed at $19.16 on Nov. 29.

Read More
ASLAN Pharma in licensing pact with A*STAR

Closely-held ASLAN Pharmaceuticals has licensed a novel immuno-oncology antibody, targeting RON (Recepteur d’Origine Nantais), from Singapore’s Agency for Science, Technology and Research (A*STAR).

RON is a receptor tyrosine kinase, and an overexpression of RON leads to increased tumor metastasis. As a result, RON activation in tumour cells promotes aggressive disease. 

Read More